Physician profile
Stanley Penc
NPI 1003078031
$657,428.34
in general payments reported to CMS, 2019-2025
28 companies · $202K in 2025
The $202K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $45K · 2021: $47K · 2022: $115K · 2023: $77K · 2024: $113K · 2025: $202K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $314K · Consulting Fee: $26K · Travel and Lodging: $24K · Food and Beverage: $16K · Honoraria: $11K · Education: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $314,134.00 |
| Consulting Fee | $26,134.00 |
| Travel and Lodging | $24,056.90 |
| Food and Beverage | $15,794.06 |
| Honoraria | $11,475.00 |
| Education | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $222,602.72 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $202,119.69 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Amgen INC. | $97,817.45 | 2019-2025 | Uplizna |
| Tg Therapeutics, INC. | $70,273.05 | 2023-2025 | |
| Abbvie INC. | $21,856.35 | 2022-2025 | |
| Axsome Therapeutics, INC. | $12,507.90 | 2025 | Symbravo |
| Genentech USA, INC. | $9,075.89 | 2021-2024 | Ocrevus, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $7,394.70 | 2019-2025 | |
| Pfizer INC. | $5,241.26 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,153.33 | 2021-2023 | |
| Celgene Corporation | $1,385.85 | 2021-2023 | Zeposia |
| Genentech, INC. | $1,260.00 | 2021 | |
| Genzyme Corporation | $541.15 | 2019-2025 | |
| Lilly USA, LLC | $347.14 | 2019-2024 | Kisunla |
| Horizon Therapeutics Plc | $335.35 | 2023 | Uplizna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $311.69 | 2022-2023 | Vyvgart |
| Allergan, INC. | $218.75 | 2019 | |
| Mdd US Operations, LLC | $209.24 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $177.33 | 2021 | |
| Eisai INC. | $152.97 | 2023-2025 | |
| Livanova USA, INC. | $144.80 | 2019 | |
| Lundbeck LLC | $122.64 | 2024-2025 | Vyepti |
| Abbott Laboratories | $68.81 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $37.95 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $30.99 | 2022 | |
| Sk Life Science, INC. | $14.50 | 2023 | |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Penc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.